SPPI Spectrum Pharmaceuticals, Inc.

5.75
-0.17  -3%
Previous Close 5.92
Open 5.92
Price To book 2.14
Market Cap 451.51M
Shares 78,523,000
Volume 541,102
Short Ratio 7.08
Av. Daily Volume 877,964

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced March 30, 2017 with preliminary data due by the end of 2017.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Phase 2 initiated March 2016. Data due by the end of 2017.
Poziotinib
Breast cancer
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. Comapny has received a new SPA from the FDA on a new Phase 3 study design. Trial to be initiated 3Q 2017.
QAPZOLA - Apaziquone
Bladder cancer
Phase 3 trial began enrollment January 2016. 75% complete as of May 2017. Enrollment to be completed 2017 with BLA filing due 2018.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer

Latest News

  1. Top 4 Small-Cap Stocks for 2017
  2. Edited Transcript of SPPI earnings conference call or presentation 2-May-17 8:30pm GMT
  3. Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17
  4. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : May 8, 2017
  5. Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
  6. Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SPPI-US : May 5, 2017
  7. Why Spectrum Pharmaceuticals Stock Is Sinking Today
  8. Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma
  9. Spectrum Pharma reports 1Q loss
  10. Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
  11. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : April 27, 2017
  12. Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4
  13. Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast
  14. Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals
  15. Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SPPI-US : April 14, 2017
  16. Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
  17. Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate
  18. Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017
  19. Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations